Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVAL: VB-111 plus paclitaxel in platinum-resistant ovarian cancer
NCT03398655Phase 3Completed
- Sponsor
- VBL Therapeutics
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 5
01
Overview
A Phase 3 trial of ofranergene obadenovec in ovarian cancer, sponsored by VBL Therapeutics. Started Dec 2017; status: completed.
02
Drugs
ofranergene obadenovec
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03398655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398655.